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A B S T R A C T   
Background: Longer serum half-lives of perfluoroalkyl substances (PFAS) in humans compared to other species 
has been attributed to differences in the activity of organic anion transporters (OAT). 
Methods: Among 56,175 adult participants in the community-based C8 Health Project, 23 subjects were taking 
the uricosuric OAT-inhibitor probenecid, and 36 subjects were taking the bile acid sequestrant cholestyramine. In 
regression models of log transformed serum PFAS, medication effects were estimated in terms of mean ratios, 
adjusting for age, gender, BMI, estimated glomerular filtration rate (eGFR) and water-district of residence. 
Results: Probenecid was associated with modest, but not statistically significant increases in serum PFAS con-
centrations. In contrast, cholestyramine significantly lowered serum PFAS concentrations, notably for per-
fluorooctane sulfonic acid (PFOS). 
Conclusions: The effectiveness of cholestyramine in a community setting supports the importance of gastroin-
testinal physiology for PFAS excretion kinetics, especially for PFOS. We did not find clear evidence that pro-
benecid, an inhibitor of OAT, affects PFAS clearance.   
1. Introduction 
Per- and polyfluoroalkyl substances (PFAS) are anthropogenic and 
environmentally persistent compounds. Several of these, including 
perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) 
are nearly ubiquitous in the environment and can be detected in the 
blood of most inhabitants of industrialized or industrializing nations (K. 
H. Harada et al., 2010). The presence of PFAS in inhaled air, or ingested 
food and water, may be explained by pollution related to their wide-
spread use in fire-fighting foams, the manufacture of fluoropolymers and 
in other industrial processes, as well as to their residual presence in 
building structural materials, outdoor soil, drinking water, indoor dusts, 
food packaging materials, and a wide variety of consumer products 
(Gluge et al., 2020; Lindstrom et al., 2011; Liu et al., 2013; Strynar and 
Lindstrom, 2008). 
PFAS are well absorbed by humans (Kudo and Kawashima, 2003), 
with average serum half-lives estimated to be about 3 years for PFOA 
(Bartell et al., 2010; Li et al., 2018; Seals et al., 2011) and approximately 
4–5 years for PFOS (Li et al., 2018; Olsen et al., 2007). Inter-individual 
variation in elimination rates and half-life values for PFOA, PFOS and 
PFHxS ranging from 1 to 10 years have been noted (Li et al., 2018). 
Important routes of elimination include urinary and biliary excretion, 
with urinary excretion generally considered to be predominating for 
most PFAS compounds (Kudo and Kawashima, 2003). Compared to 
animal species, longer serum PFAS half-lives in humans (Kudo and 
Kawashima, 2003) are potentially explained by differences in secretion 
and reabsorption in kidney and gut, mediated by active renal tubular 
organic anion transporters (OATs) (K. Harada et al., 2005; Kudo et al., 
2002; Kudo and Kawashima, 2003; Nakagawa et al., 2009) and organic 
anion transporter polypeptides (OATp) (Yang et al., 2009, 2010; Zhao 
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et al., 2017), although the interactions of renal secretion, reabsorption, 
and total renal excretion of PFAS by OATs in humans are complex and 
incompletely understood (Fabrega et al., 2014; Han et al., 2012; Loc-
cisano et al., 2013). Two OATs (OAT1, OAT3) are involved in renal 
tubular secretion, and have been reported to have high affinity for PFOA 
in humans and in rats (Nakagawa et al., 2008). Nevertheless, poor renal 
excretion by OATs has been implicated as a likely contributor to the 
human species-specific slow excretion of PFAS such as PFOA (K. Harada 
et al., 2005). In contrast, OAT4 and OATp are considered to be involved 
in tubular reabsorption of PFAS (Andersen et al., 2008; Nakagawa et al., 
2009), as well as PFAS membrane effects in the gut (Kimura et al., 2020) 
and in other organs (Sabovic et al., 2019). Highly active renal (and gut) 
reabsorption might therefore represent a fundamental mechanism of the 
long human half-life of the long-chain PFAS such as PFOA and PFOS 
(Han et al., 2012). 
Pharmaceutical agents prescribed for many reasons may interact 
with excretion of PFAS in community settings. Consideration of their 
activity provides a practical, observational opportunity to address 
knowledge gaps concerning excretion. Probenecid inhibits OAT1 and 
OAT3. It is prescribed primarily because it competitively interferes with 
renal tubular transport of uric acid, leading to increased uric acid 
excretion and thus lower serum uric acid levels. OAT1 and OAT3 have 
also been hypothesized to play a role in the renal excretion of PFAS 
(Nakagawa et al., 2008). Probenecid-induced inhibition of OAT1 and 
OAT3 therefore suggests the a priori hypothesis that those taking pro-
benecid could have slower renal excretion and higher PFAS, opposite to 
what is known about probenecid’s effect on uric acid. Rodents exposed 
to probenecid show reduced renal clearance and higher serum PFOA 
concentrations, consistent with a role of OAT1 and OAT3 in rodent PFAS 
excretion (Kudo et al., 2002), although there are also interspecies and 
reabsorption reasons to question how important such a role could be in 
humans (Nakagawa et al., 2008; Yang et al., 2009, 2010). 
PFAS also enter the intestine as a component of bile; where they can 
be reabsorbed and returned to the liver through enterohepatic circula-
tion, in a repeating cycle of biliary excretion and reabsorption (Jandacek 
and Tso, 2007; Lau et al., 2007). Cholestyramine, a bile acid sequestrant 
resin historically used in the treatment of lipid disorders, increases the 
excretion of cholesterol in the form of bile acids rather than allowing for 
enterohepatic circulation. Cholestyramine also promotes the removal of 
anionic contaminants, such as the obsolete pesticide chlordecone, 
through fecal excretion (Cohn et al., 1978). Johnson et al. demonstrated 
that feeding cholestyramine to rats, following administration of either 
PFOA or PFOS, increased PFAS fecal elimination (Johnson et al., 1984). 
Cholestyramine treatment has been shown to result in increased fecal 
PFAS excretion under short-term observed conditions in a small human 
population (n = 8) (Genuis et al., 2013). An earlier case report also 
showed that more prolonged treatment resulted in diminished serum 
concentrations, notably for PFOS, in a highly exposed individual (Genuis 
et al., 2010). 
The C8 Health Project enrolled 69,030 participants of all ages from 
six water districts with varying degrees of PFOA water contamination, 
and it measured a suite of PFAS compounds in most of them (Frisbee 
et al., 2009). The large population size provided an opportunity to 
investigate the effects of relatively uncommon drugs such as the urico-
suric drug probenecid and the bile acid sequestrant cholestyramine on 
serum concentrations of PFAS in an unsupervised population setting. We 
are not aware of an existing investigation of the influence of OAT on 
PFAS excretion in a community exposure population, nor of a published 
study that investigates the influence of chronically prescribed pharma-
ceutical medications on enhancing or delaying excretion. 
2. Methods 
2.1. Study population 
The C8 Health Project arose from a court-directed settlement 
following the discovery of PFOA contamination of six water districts in 
the mid-Ohio Valley region of Ohio and West Virginia. The circum-
stances of the settlement and the independently administered popula-
tion survey methodology have been described (Frisbee et al., 2009). 
Briefly, participants filled out an extensive health survey in 2005− 6 
including socioeconomic, employment, and personal health informa-
tion, diagnoses, and prescriptions as well as over-the-counter drugs. 
Survey participation has been estimated to represent 80–81 % of adult 
residents then residing in the six affected water districts (Frisbee et al., 
2009; Steenland et al., 2009a). This study of deidentified participant 
data was conducted under a West Virginia University IRB. 
The following PFAS were detected in the serum of the vast majority 
of 56,554 adult survey participants for the initial survey: PFOA, PFOS, 
PFHxS (perfluorohexane sulfonate), and PFNA (perfluorononanoic 
acid). We included 56,175 participants who had no missing values for all 
four analytes as the final study population. Data for six other PFAS 
species, each with numerous values below the limit of detection, were 
not considered to be suited for the purpose of this study. Because our 
outcome variable is related to excretion kinetics, and the proportion 
below the LOD is small, and the population is large, we excluded rather 
than used surrogate variables for the very rare serum concentrations 
below the level of detection for the four PFAS considered. No takers of 
either drug were excluded by this strategy. Participants providing 
ambiguous responses concerning present use of the medications of in-
terest were excluded. 
2.2. Laboratory methods 
PFAS serum concentrations were determined by a modification to a 
previously described procedure combining protein precipitation 
extraction with reverse-phase high-performance liquid chromatog-
raphy/tandem mass spectrometry. A triple quadrupole mass spectrom-
eter in selected reaction monitoring mode detected the M/Z transitions 
of individual perfluorocarbon compounds and the appropriate species of 
13C-PFAS surrogate. Additional details of the technique and quality 
assurance protocols have been published elsewhere (Frisbee et al., 
2009). 
2.3. Study design and statistical analysis 
The aim of the study was to separately compare serum levels of four 
PFAS compounds between users vs. nonusers of probenecid and chole-
styramine in a survey containing self-reported information about phar-
maceutical use. All names of pharmaceuticals containing probenecid, 
commercial names and possible misspellings were searched across the 
medications database of the C8 Health Project to identify probenecid 
users in the study. This process was repeated for cholestyramine. The 
distribution of the four PFAS studied was skewed; therefore, we log 
transformed these variables. We performed linear regression of natural 
log-transformed PFAS level as the outcome variable and probenecid or 
cholestyramine use as the main exposure, additionally adjusting for 
covariates including age, gender, socioeconomic status (SES), estimated 
glomerular filtration rate (eGFR), water district, and BMI in the full 
model. Water district was also included in the event that prescribing 
habits varied within the narrow geography of six water districts within 
the Ohio River Valley; the water districts definitely varied substantially 
in their historic exposures to PFOA (Steenland et al., 2009a). 
The statistical analysis plans for probenecid and cholestyramine 
were similar, but the analyses were conducted separately. We expo-
nentiated the coefficients from the regression models to calculate the 
ratio of geometric mean of serum PFAS and the 95 % confidence interval 
in the probenecid or cholestyramine users, relative to their respective 
comparison groups, i.e., the comparison population not taking these 
pharmaceuticals. The power to detect one standard deviation (SD) dif-
ference in log-transformed PFAS between the case and control pop-
ulations was more than 95 % for the probenecid analysis and more than 
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99 % for the cholestyramine analysis (e.g., for log-transformed PFOS, 
one SD is 0.83 for probenecid analysis and 0.76 for cholestyramine 
analysis). All statistical analyses were performed using SAS version 9.2 
(SAS Institute, Cary, NC). 
2.4. Sensitivity analysis 
To address the possibility of over-adjustment, we performed sensi-
tivity analyses for the same comparisons without adjustment for eGFR, 
and also without adjustment for water district. We also carried out a 1:3 
case-control comparison matched on gender and birth year, in order to 
reassure that the age adjustment had been complete in the regression 
analysis. 
3. Results 
3.1. Probenecid and PFAS 
Demographic data are presented for the probenecid comparisons in 
Table 1. Probenecid users (mean age 64.1) were substantially older than 
the entire adult population with serum PFAS concentrations (45.3). The 
male predominant 3:1 gender ratio was also expected because the usual 
indication, gout, is more common in older males, as was the lower eGFR 
in older individuals with indications for using a uricosuric medication. 
Probenecid users had higher geometric mean PFAS than nonusers 
(Table 2) in the unadjusted comparisons, and PFAS levels were previ-
ously known to be higher for males and to rise with age in this popu-
lation (Frisbee et al., 2009). However, none of the probenecid-related 
differences approached statistical significance in a multivariable 
adjusted model which included age, gender, BMI, water district, and 
eGFR. A sensitivity analysis showed that this finding was not due to 
overadjustment for eGFR, with geometric mean ratio of 1.23 (C.I. 
0.85− 1.78) for PFOA (adjusted for age, gender, BMI, and water district), 
and still smaller mean ratios were noted for other analytes. 
3.2. Cholestyramine and PFAS 
Table 3 provides demographic data for the cholestyramine compar-
isons. The population of medication takers (mean age 54.6) is again 
older, as expected. The male predominance seen for probenecid does not 
apply to cholestyramine, also as expected. 
In contrast to findings for probenecid, cholestyramine users had 
unequivocally different (lower) PFAS serum concentrations than non-
users (Table 4) in the multivariable adjusted models. This included the 
striking difference for PFOS (PFOS serum concentration 0.07 of the 
serum concentrations in non-users 95 %, C.I. 0.05− 0.08. p = 0.00), a 
finding consistent with a previously reported results of short-term trial 
by Genuis et al. (2010). Only PFOA results failed to be highly significant 
in the unadjusted models, and they were significant following 
adjustment (0.55 lower, 95 % C.I. 0.41− 0.74, p = 0.00). Sensitivity 
testing without eGFR made no difference to the cholestyramine findings. 
Comparisons with a 3:1 case-control comparison matched on age and 
sex revealed identical findings, except for wider confidence intervals 
(and therefore even less apparent differences for probenecid compari-
sons), reflecting the smaller reference population size. This similarity is 
expected since cases and controls came from the same population. 
4. Discussion 
Our study confirms the strong effect of cholestyramine and does not 
demonstrate a clear effect of OAT inhibition by probenecid on serum 
PFAS concentrations in a community setting. The negative result for 
probenecid implies little effect or no effect of OAT1 and OAT3 inhibition 
on PFAS excretion kinetics. The small population taking probenecid 
does not allow us to confidently choose between these possibilities. This 
weak or nil association is physiologically consistent with the observation 
that PFAS excretion, which is facilitated in other species by OAT, is 
inefficient in humans (Kudo and Kawashima, 2003) and likely 
Table 1 
Baseline characteristics of the study population*.  
Characteristics Whole cohort (n =
56,554) 
Probenecid users (n =
23) 
Age (years) 45.30 ± 16.28 64.15 ± 11.28 
Female (%) 29,675 (52.47) 6 (26.09) 
Body mass index (kg/m2) 28.67 ± 7.65 30.49 ± 3.98 
Estimated glomerular filtration 
ratea 
79.44 ± 18.38 59.29 ± 19.59 
Serum uric acid (mg/dL) 5.58 ± 1.55 6.70 ± 1.57 
PFHxS (C6s, ng/mL) 2.97 ± 2.27 3.88 ± 2.67 
PFOA (C8, ng/mL) 32.91 ± 3.51 90.47 ± 5.02 
PFOS (C8s, ng/mL) 19.09 ± 2.02 28.24 ± 2.25 
PFNA (C9, ng/mL) 1.36 ± 1.65 1.53 ± 1.85  
* Data presented are number (percentages) or mean values ± standard devi-
ation (SD), as appropriate for the variable. 
a ml/min/1.73 m2. 
Table 2 











ratio (95% CI) 
PFHxS     
Probenecid 
non-users 
56152 2.97 (2.27) 1 (referent) 1 (referent) 
Probenecid 
users 
23 3.88 (2.67) 1.30 
(0.94− 1.83) 
1.06 (0.76− 1.47) 
p-value   0.11 0.74 












1.23 (0.85− 1.78) 
p-value   0.00 0.28 












1.13 (0.85− 1.50) 
p-value   0.01 0.39 
PFNA     
Probenecid 
non-users 
56152 1.36 (1.65) 1 (referent) 1 (referent) 
Probenecid 
users 
23 1.53 (1.85) 1.12 
(0.92− 1.38) 
1.02 (0.83− 1.26) 
p-value   0.25 0.84  
* Adjusted for age, gender, body mass index, water district, and estimated 
glomerular filtration rate. 
Table 3 
Baseline characteristics of the study population*.  
Characteristics Whole cohort (n =
56,554) 
Cholestyramine users (n =
36) 
Age (years) 45.30 ± 16.28 54.68 ± 15.33 
Female (%) 29.67 (52.47) 23 (63.89) 
Body mass index (kg/m2) 28.67 ± 7.65 28.33 ± 6.24 
Estimated glomerular 
filtration ratea 
79.44 ± 18.38 72.96 ± 17.67 
Serum uric acid (mg/dL) 5.58 ± 1.55 5.85 ± 1.64 
PFHxS (C6s, ng/mL) 2.97 ± 2.27 1.12 ± 2.89 
PFOA (C8, ng/mL) 32.91 ± 3.51 23.76 ± 3.70 
PFOS (C8s, ng/mL) 19.09 ± 2.02 1.25 ± 5.24 
PFNA (C9, ng/mL) 1.36 ± 1.65 0.51 ± 2.03  
* Data presented are number (percentages) or mean values ± standard devi-
ation (SD), as appropriate for the variable. 
a ml/min/1.73 m2. 
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dominated by reabsorption kinetics in the healthy kidney (Fenton et al., 
2020). It is also consistent with recent findings that inherited allelic OAT 
variants do not materially affect PFAS serum concentrations (Ingelido 
et al., 2018). It is further consistent with recent findings that moderate to 
severe renal failure is associated with increased serum PFAS excretion 
(Jain and Ducatman, 2019c), especially in the presence of albuminuria 
(Jain and Ducatman, 2019b). If reabsorption dominates human renal 
PFAS kinetics as hypothesized, then albuminuria and advancing renal 
failure are expected to lead to lower serum PFAS whereas inhibition of 
OAT might have little effect on serum PFAS. 
In contrast to the nil or equivocal findings with the OAT inhibitor 
probenecid, participants taking the anion exchange resin cholestyr-
amine experienced definitively reduced PFAS serum concentrations in a 
community setting. Our findings provide practical confirmation at a 
population level for previous case reports that this fecal excretory route 
for PFAS is greatly enhanced by taking cholestyramine (Genuis et al., 
2010, 2013) especially for PFOS. The effect in our data is that the 
relative potency for decrease in PFAS in cholestyramine takers is 
PFOS>>PFNA > PFHxS > PFOA. This relative degree of implied effec-
tiveness might be different in populations with different initial and 
ongoing PFAS exposures. The cholestyramine data are also consistent 
with the observation that gastrointestinal kinetics contribute to 
inter-individual uncertainties for predicting measures of serum PFAS 
(Fabrega et al., 2014). 
PFAS exposures have been previously shown to be independently 
associated with significant increases in serum uric acid in this commu-
nity population (Steenland et al., 2010) and in other populations where 
serum PFAS has been measured (Geiger et al., 2013; Gleason et al., 2015; 
Kataria et al., 2015; Scinicariello et al., 2020; Shankar et al., 2011; Zeng 
et al., 2019) and in a PFOA-exposed workforce (Costa et al., 2009). 
“Confounding by indication” therefore deserves discussion because gout 
is the common indication for probenecid. However, to the degree that 
such indication bias may exist for probenecid per se, it is a priori more 
likely to lead to higher serum PFAS, given that higher uric acid is 
associated with higher serum PFAS, whereas our analysis found no as-
sociation or an equivocal association with probenecid. A secondary 
mechanistic consideration for such a bias is via the effect of gout upon 
kidney function. However, our data show that adjustment for eGFR does 
not affect the findings, and it has been independently shown that the 
PFAS-uric acid association is not due to confounding by renal disease 
(Jain and Ducatman, 2019a). If these potential sources of bias are 
relevant to our findings, they would tend to overstate an association that 
is already equivocal or nil in our data, reinforcing the inference that 
pharmacologic inhibition of OAT1 and 3 has small or no effect on serum 
PFAS. 
Sources of bias related to cholestyramine can also be considered in a 
community setting. Cholestyramine is generally mixed into and taken 
with a liquid, often water. Although we have no data to address water 
intake, this medication requirement could have increased PFOA intake 
by inhabitants of the contaminated water districts who participated in 
our study, especially in the case of cholestyramine users. If this theo-
retical source of bias is important, the data may understate the excretory 
effect of cholestyramine, especially upon PFOA, which was in the 
drinking water. Further, an historic indication for cholestyramine is 
elevated total and LDL cholesterol, which are also associated with higher 
PFOA and PFOS serum concentrations in multiple studies including in 
this population (Steenland et al., 2009a, 2009b). If confounding by 
indication does influence our cholestyramine findings, then the excre-
tory effect of cholestyramine may be slightly stronger than the data 
indicate, especially for PFOA. Finally, it is worth considering if the 
strong negative impact of cholestyramine on serum PFAS shown in these 
data, notably on PFOS, could be a source of bias if not adjusted for in 
other previously reported associations such as to lipid outcomes. How-
ever, the prevalence of use is very low (36/56175) in this population, 
and some studies of PFAS associations with lipids have excluded subjects 
taking lipid lowering agents, including in this population (Fitz-Simon 
et al., 2013; Steenland et al., 2009b). 
An obvious study weakness is its prevalence survey design. Preva-
lence studies have important limitations as regards causation. However, 
the findings are highly consistent with two short-term demonstrations of 
cholestyramine used as an excretory agent of PFAS in an individual or 
small group (Genuis et al., 2010, 2013) as well as with toxicologic data 
concerning the effects of cholestyramine on PFAS kinetics (Jandacek 
and Tso, 2007; Johnson et al., 1984; Lau et al., 2007) and with historic 
human data concerning cholestyramine treatment of other anionic 
contaminants (Cohn et al., 1978). The data in this cross sectional study 
cannot address the time course required for cholestyramine to reduce 
PFAS. The data also do not address permanence of cholestyramine ef-
fects on serum PFAS following cessation of medication. Because PFAS 
are known to be stored in a variety of tissues other than serum, there is 
possibility that some “bounce-back” could occur following the cessation 
of treatment due to tissue compartment re-equilibration. 
Our data provide evidence that cholestyramine enhances PFAS 
excretion in a community setting, especially for PFOS. This information 
is potentially interesting to exposed workers and inhabitants of com-
munities with known PFAS water contamination, as there are a growing 
list of human health effects associated with PFAS exposure and parallel 
toxicology findings of concern (Fenton et al., 2020; Hagstrom et al., 
2021). Importantly, it is possible but not proved by these data that 
addressing the levels of a circulating toxicant risk factor with a phar-
maceutical agent will necessarily also decrease the health risk of expo-
sure. We do not know if and to what degree alterations in liver 
metabolism and other changes following from PFAS exposure are 
reversible, although modeled exposure studies in this same population 
do suggest that the lipid associations may respond to declining serum 
PFAS (Fitz-Simon et al., 2013). Access to available means such as 
pharmaceutical agents to decrease serum PFAS concentrations is a 
repeated inquiry posed to care givers by members of exposure pop-
ulations. We are providing data that excretion can be enhanced by 
cholestyramine, but the cross-sectional data do not directly address the 
impact on the burden in other tissues. More fundamentally, the data 
cannot provide evidence that increasing the speed of excretion 
Table 4 












ratio (95% CI) 
PFHxS     
Cholestyramine 
non-users 
56139 2.97 (2.27) 1 (referent) 1 (referent) 
Cholestyramine 
users 




p-value   0.00 0.00 














p-value   0.12 0.00 





1 (referent) 1 (referent) 
Cholestyramine 
users 




p-value   0.00 0.00 
PFNA     
Cholestyramine 
non-users 
56139 1.36 (1.65) 1 (referent) 1 (referent) 
Cholestyramine 
users 




p-value   0.00 0.00  
* Adjusted for age, gender, body mass index, water district, and estimated 
glomerular filtration. 
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otherwise improves the health of those exposed to PFAS. That conver-
sation initiated by individuals known or inferred to have heavy internal 
PFAS contamination can be guided by evidence that excretion can be 
enhanced, especially for PFOS, but is not yet informed by clinical trial 
evidence of the balance of risks and benefits for medications such as 
cholestyramine that appear to decrease human biological PFAS burdens. 
5. Conclusion 
We conclude that bile acid sequestrant cholestyramine prescribed for 
reasons that did not consider PFAS can nevertheless assist in the more 
rapid excretion of PFAS in community settings, especially PFOS and, to a 
lesser degree, other PFAS including PFNA, PFHxS, and PFOA. Using the 
same method, we sought but did not find clear-cut evidence that pro-
benecid, an inhibitor of organic anion transporters (OAT), affects PFAS 
clearance. The cholestyramine results provide confirmation that 
gastrointestinal kinetics can be important to inter-individual differences 
in serum PFAS concentrations, especially for long-chain sulfonate 
compounds. The probenecid results support the understanding that 
reabsorption plays a dominant kinetic role for PFAS in the healthy 
kidney. 
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